Adamis Pharmaceuticals Completes Acquisition of a Technology for a Potential Universal Cancer Vaccine
4/19/2011 10:27:35 AM
SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California. The patent comprises “Composition and Method for Inducing and Enhancing a Telomerase Reverse Transciptase-Reactive Cytotoxic T Lymphocyte Response.” The technology was discovered and developed by Maurizio Zanetti, M.D., at the University of California, San Diego (UCSD). In addition to this license, Adamis licensed a complementary patent, “Cancer Immunotherapy and Diagnosis Using Universal Tumor Associated Antigens, Including Human Telomerase Reverse Transciptase,” based on similar technology from the Dana-Farber/Harvard Cancer Center. This technology constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, which activates the body’s natural defense machinery to stimulate an immune response against one of nature’s universal tumor markers, i.e. telomerase. The vaccine utilizes the patient’s own B cells as antigen producing and antigen presenting cells. B cells represent approximately 12% of the circulating blood cells.
comments powered by